Zacks
Intuitive Surgical, Inc. (ISRG) Stock Moves -1.32%: What You Should Know
📈
AI Sentiment
Highly Positive
8/10
- Home
- ISRG
as of 03-06-2026 3:52pm EST
$489.28
$7.42
-1.49%
Intuitive develops, produces, and markets a robotic system for assisting minimally invasive surgery. It also provides the instrumentation, disposable accessories, and warranty services for the system. The company has placed more than 10,000 da Vinci systems in hospitals worldwide, with more than 6,000 installations in the US and a growing number in emerging markets.
| Founded: | 1995 | Country: | United States |
| Employees: | N/A | City: | SUNNYVALE |
| Market Cap: | 176.2B | IPO Year: | 1998 |
| Target Price: | $612.40 | AVG Volume (30 days): | 1.6M |
| Analyst Decision: | Buy | Number of Analysts: | 15 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 7.87 | EPS Growth: | 22.59 |
| 52 Week Low/High: | $425.26 - $603.88 | Next Earning Date: | 04-20-2026 |
| Revenue: | $10,064,700,000 | Revenue Growth: | 20.51% |
| Revenue Growth (this year): | 16.73% | Revenue Growth (next year): | 13.86% |
| P/E Ratio: | 62.99 | Index: | |
| Free Cash Flow: | N/A | FCF Growth: | +91.03% |
AI-Powered ISRG Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 2 days ago
AI Recommendation
hold
Model Accuracy: 68.10%
68.10%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Stock Insider Trading Activity of Intuitive Surgical Inc. (ISRG)
Brosius Mark
Sell
SVP & Chief Mfg and Supply Cha
ISRG Mar 5, 2026
Avg Cost/Share
$495.20
Shares
648
Total Value
$320,889.60
Owned After
2,906
SEC Form 4
Brosius Mark
Sell
SVP & Chief Mfg and Supply Cha
ISRG Mar 4, 2026
Avg Cost/Share
$498.68
Shares
2,362
Total Value
$1,177,883.10
Owned After
2,906
SEC Form 4
Brosius Mark
Sell
SVP & Chief Mfg and Supply Cha
ISRG Mar 3, 2026
Avg Cost/Share
$488.10
Shares
648
Total Value
$316,288.80
Owned After
2,906
SEC Form 4
Curet Myriam
Sell
EVP & Chief Medical Officer
ISRG Mar 3, 2026
Avg Cost/Share
$487.18
Shares
4,728
Total Value
$2,303,387.04
Owned After
409
SEC Form 4
Widman Fredrik
Sell
VP Corporate Controller
ISRG Mar 3, 2026
Avg Cost/Share
$487.18
Shares
118
Total Value
$57,487.24
Owned After
1,026
SEC Form 4
Curet Myriam
Sell
EVP & Chief Medical Officer
ISRG Mar 2, 2026
Avg Cost/Share
$492.59
Shares
125
Total Value
$61,573.75
Owned After
409
SEC Form 4
Curet Myriam
Sell
EVP & Chief Medical Officer
ISRG Feb 27, 2026
Avg Cost/Share
$499.71
Shares
2,345
Total Value
$1,171,819.95
Owned After
409
SEC Form 4
Widman Fredrik
Sell
VP Corporate Controller
ISRG Feb 27, 2026
Avg Cost/Share
$499.71
Shares
249
Total Value
$124,427.79
Owned After
1,026
SEC Form 4
WADORS PATRICIA L
Sell
SVP Chief Human Resources Offi
ISRG Feb 27, 2026
Avg Cost/Share
$499.71
Shares
220
Total Value
$109,936.20
Owned After
0
SEC Form 4
Curet Myriam
Sell
EVP & Chief Medical Officer
ISRG Feb 11, 2026
Avg Cost/Share
$494.96
Shares
421
Total Value
$208,378.16
Owned After
409
SEC Form 4
| Insider | Ticker | Relationship | Date | Transaction | Avg Cost | Shares | Total Value | Owned After | SEC Forms |
|---|---|---|---|---|---|---|---|---|---|
| Brosius Mark | ISRG | SVP & Chief Mfg and Supply Cha | Mar 5, 2026 | Sell | $495.20 | 648 | $320,889.60 | 2,906 | |
| Brosius Mark | ISRG | SVP & Chief Mfg and Supply Cha | Mar 4, 2026 | Sell | $498.68 | 2,362 | $1,177,883.10 | 2,906 | |
| Brosius Mark | ISRG | SVP & Chief Mfg and Supply Cha | Mar 3, 2026 | Sell | $488.10 | 648 | $316,288.80 | 2,906 | |
| Curet Myriam | ISRG | EVP & Chief Medical Officer | Mar 3, 2026 | Sell | $487.18 | 4,728 | $2,303,387.04 | 409 | |
| Widman Fredrik | ISRG | VP Corporate Controller | Mar 3, 2026 | Sell | $487.18 | 118 | $57,487.24 | 1,026 | |
| Curet Myriam | ISRG | EVP & Chief Medical Officer | Mar 2, 2026 | Sell | $492.59 | 125 | $61,573.75 | 409 | |
| Curet Myriam | ISRG | EVP & Chief Medical Officer | Feb 27, 2026 | Sell | $499.71 | 2,345 | $1,171,819.95 | 409 | |
| Widman Fredrik | ISRG | VP Corporate Controller | Feb 27, 2026 | Sell | $499.71 | 249 | $124,427.79 | 1,026 | |
| WADORS PATRICIA L | ISRG | SVP Chief Human Resources Offi | Feb 27, 2026 | Sell | $499.71 | 220 | $109,936.20 | 0 | |
| Curet Myriam | ISRG | EVP & Chief Medical Officer | Feb 11, 2026 | Sell | $494.96 | 421 | $208,378.16 | 409 |
Earnings Transcripts
SEC 8-K filings with transcript text
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 22, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 22, 2026 · 100% conf.
AI Prediction SELL
1D
-2.42%
$515.20
5D
-3.14%
$511.43
20D
-5.46%
$499.15
Price: $528.00 Prob +5D: 0% AUC: 1.000
0001035267-26-000006
isrg-202601220001035267FALSE00010352672026-01-222026-01-22
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 22, 2026
INTUITIVE SURGICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-30713 77-0416458 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
1020 Kifer Road Sunnyvale, California 94086 (Address of Principal Executive Offices) (zip code) Registrant’s telephone number, including area code: (408) 523-2100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ISRG The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02.Results of Operations and Financial Condition.
On January 22, 2026, Intuitive Surgical, Inc. (“Intuitive”) issued a press release announcing its financial results for the quarter ended December 31, 2025. A copy of the press release is furnished hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of Intuitive under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01.Financial Statements and Exhibits.
d) Exhibits. Exhibit No.Description
99.1Press release issued by Intuitive Surgical, Inc., dated January 22, 2026
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INTUITIVE SURGICAL, INC.
Date: January 22, 2026 By:/s/ JAMIE E. SAMATH Name: Jamie E. Samath
Title: Executive Vice President, Chief Financial Officer
2025 Q4 Q4 2025 Earnings
8-K SELL Jan 14, 2026 · 100% conf.
2025
Q4
Q4 2025 Earnings
8-K SELLJan 14, 2026 · 100% conf.
AI Prediction SELL
1D
-2.42%
$515.20
5D
-3.14%
$511.43
20D
-5.46%
$499.15
Price: $528.00 Prob +5D: 0% AUC: 1.000
0001035267-26-000003
isrg-202601140001035267false00010352672026-01-142026-01-14
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): January 14, 2026
INTUITIVE SURGICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-30713 77-0416458 (State or other jurisdiction of incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
1020 Kifer Road Sunnyvale, California 94086 (Address of principal executive offices) (zip code) Registrant’s telephone number, including area code: (408) 523-2100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions: ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425) ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12) ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b)) ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ISRG The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ☐ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐
Item 2.02.Results of Operations and Financial Condition.
On January 14, 2026, Intuitive Surgical, Inc. (“Intuitive”) issued a press release announcing certain unaudited preliminary fourth quarter and full year 2025 financial results. A copy of the press release is furnished hereto as Exhibit 99.1. Additional unaudited preliminary revenue and procedure information is provided in the tables attached hereto as Exhibit 99.2, which has also been posted to the Investor Relations section of the Intuitive website at: https://isrg.gcs-web.com/. The information in this Current Report on Form 8-K, including Exhibits 99.1 and 99.2, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of Intuitive under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01.Financial Statements and Exhibits.
(d) Exhibits. The following exhibits are furnished with this report on Form 8-K: Exhibit No. Description
99.1Press release issued by Intuitive Surgical, Inc., dated January 14, 2026.
99.2Unaudited preliminary revenue and procedure information, as of January 14, 2026.
104Cover Page Interactive Data File (embedded within the Inline XBRL document).
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, as amended, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INTUITIVE SURGICAL, INC.
Date: January 14, 2026 By: /s/ JAMIE E. SAMATH Name: Jamie E. Samath
Title: Executive Vice President, Chief Financial Officer
2025 Q3 Q3 2025 Earnings
8-K Oct 21, 2025
2025
Q3
Q3 2025 Earnings
8-KOct 21, 2025
0001035267-25-000206
isrg-202510210001035267FALSE00010352672025-10-212025-10-21
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934 Date of Report (Date of earliest event reported): October 21, 2025
INTUITIVE SURGICAL, INC.
(Exact name of registrant as specified in its charter)
Delaware 000-30713 77-0416458 (State or Other Jurisdiction of Incorporation) (Commission File Number) (I.R.S. Employer Identification No.)
1020 Kifer Road Sunnyvale, California 94086 (Address of Principal Executive Offices) (zip code) Registrant’s telephone number, including area code: (408) 523-2100
Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
¨Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
¨Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
¨Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
¨Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))
Securities registered pursuant to Section 12(b) of the Act:
Title of each class Trading Symbol(s) Name of each exchange on which registered Common Stock, par value $0.001 per share ISRG The Nasdaq Global Select Market
Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter). Emerging growth company ¨ If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ¨
Item 2.02.Results of Operations and Financial Condition.
On October 21, 2025, Intuitive Surgical, Inc. (“Intuitive”) issued a press release announcing its financial results for the quarter ended September 30, 2025. A copy of the press release is furnished hereto as Exhibit 99.1. The information in this Current Report on Form 8-K, including Exhibit 99.1, shall not be deemed “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), or otherwise subject to the liabilities under that section and shall not be deemed to be incorporated by reference into any filing of Intuitive under the Securities Act of 1933, as amended, or the Exchange Act.
Item 9.01.Financial Statements and Exhibits.
d) Exhibits. Exhibit No.Description
99.1Press release issued by Intuitive Surgical, Inc., dated October 21, 2025
104Cover Page Interactive Data File (embedded within the Inline XBRL document)
SIGNATURES
Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
INTUITIVE SURGICAL, INC.
Date: October 21, 2025 By:/s/ JAMIE E. SAMATH Name: Jamie E. Samath
Title: Executive Vice President, Chief Financial Officer
Latest Intuitive Surgical Inc. News
ISRG Breaking Stock News: Dive into ISRG Ticker-Specific Updates for Smart Investing
MT Newswires
Intuitive Surgical Insider Sold Shares Worth $1,815,062, According to a Recent SEC Filing
➖
AI Sentiment
Neutral
5/10
Simply Wall St.
Intuitive Surgical’s European Push And Cardiac Clearance Tested By Lofty Valuation
📊
AI Sentiment
Positive
7/10
Zacks
Here's Why You Should Retain Clover Stock in Your Portfolio for Now
📊
AI Sentiment
Positive
7/10
Zacks
This Top Medical Stock is a #1 (Strong Buy): Why It Should Be on Your Radar
➖
AI Sentiment
Neutral
5/10
Zacks
Intuitive Surgical Expands Direct Operational Presence in Europe
📈
AI Sentiment
Highly Positive
8/10
Zacks
Can Digital Subscriptions Become ISRG's New Revenue Stream in 2026?
📈
AI Sentiment
Highly Positive
9/10
24/7 Wall St.
BOTZ Is A Robotics ETF That Quietly Bets Big on AI Chips
📈
AI Sentiment
Highly Positive
10/10
Compare ISRG vs Leading Stocks
See how ISRG stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ISRG Intuitive Surgical Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.